PACS:NYSEPACS Group, Inc. Analysis

PACS reported $5.43 B of revenue with an 11% YoY increase, beating expectations and prompting a 16% post‑earnings price jump. The company posted a forward EPS of $2.51, translating to a forward P/E of 14.5—well below the industry average of 24.8—while the current market price of $36.28 sits above the DCF‑derived fair value of $20.06 but below the 52‑week high of $43.08. Technicals show a bullish trend with the 20‑day SMA ($36.77) above the 50‑day SMA ($35.49) and the 200‑day SMA ($28.65), yet the MACD has turned bearish and the price is testing a near‑term support level at $34.07. Volatility is elevated at 86% over the past 30 days and the stock’s beta of 0.37 indicates low market correlation, while the max drawdown of –42% underscores historical downside risk.
The earnings beat and raised guidance highlight strong operational momentum and a pipeline of attractive acquisition targets, but ongoing government investigations and internal control issues raise regulatory concerns. High leverage (debt‑to‑equity ~ 336) and a zero‑dividend policy limit cash return potential, though operating cash flow remains solid at $490 M. Overall, the stock offers growth upside relative to its valuation metrics, but investors should weigh the regulatory and leverage risks.